QIAGEN Return on Investment 2010-2022 | QGEN

Current and historical return on investment (ROI) values for QIAGEN (QGEN) over the last 10 years.
QIAGEN ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2022-03-31 $0.67B $4.72B 14.63%
2021-12-31 $0.63B $4.19B 13.64%
2021-09-30 $0.61B $4.58B 12.93%
2021-06-30 $0.53B $4.92B 11.37%
2021-03-31 $0.48B $4.78B 11.00%
2020-12-31 $0.39B $4.68B 9.27%
2020-09-30 $0.31B $4.13B 7.78%
2020-06-30 $0.06B $4.02B 1.47%
2020-03-31 $0.00B $3.88B 0.00%
2019-12-31 $-0.03B $3.96B -0.64%
2019-09-30 $-0.02B $4.16B -0.44%
2019-06-30 $0.27B $4.04B 6.67%
2019-03-31 $0.26B $4.00B 6.57%
2018-12-31 $0.27B $4.31B 6.78%
2018-09-30 $0.22B $3.59B 5.63%
2018-06-30 $0.21B $3.87B 5.07%
2018-03-31 $0.18B $3.94B 4.31%
2017-12-31 $0.15B $4.30B 3.82%
2017-09-30 $0.11B $4.31B 2.97%
2017-06-30 $0.10B $3.89B 2.65%
2017-03-31 $0.11B $3.50B 2.90%
2016-12-31 $0.10B $3.67B 2.68%
2016-09-30 $0.15B $3.74B 4.15%
2016-06-30 $0.15B $3.70B 4.14%
2016-03-31 $0.16B $3.68B 4.45%
2015-12-31 $0.18B $3.62B 5.00%
2015-09-30 $0.14B $3.58B 3.95%
2015-06-30 $0.15B $3.59B 4.01%
2015-03-31 $0.15B $3.53B 4.13%
2014-12-31 $0.16B $3.70B 4.21%
2014-09-30 $0.17B $3.75B 4.59%
2014-06-30 $0.16B $3.93B 4.23%
2014-03-31 $0.08B $3.90B 2.11%
2013-12-31 $0.06B $3.57B 1.79%
2013-09-30 $0.08B $3.52B 2.22%
2013-06-30 $0.08B $3.44B 2.42%
2013-03-31 $0.16B $3.54B 4.85%
2012-12-31 $0.17B $3.57B 5.24%
2012-09-30 $0.10B $3.16B 3.24%
2012-06-30 $0.10B $3.09B 3.11%
2012-03-31 $0.10B $3.08B 3.07%
2011-12-31 $0.10B $3.00B 3.07%
2011-09-30 $0.17B $3.03B 5.19%
2011-06-30 $0.19B $3.39B 5.58%
2011-03-31 $0.18B $3.33B 5.56%
2010-12-31 $0.19B $3.27B 5.83%
2010-09-30 $0.17B $3.25B 5.37%
2010-06-30 $0.18B $3.23B 5.52%
2010-03-31 $0.18B $3.21B 6.13%
2009-12-31 $0.18B $3.19B 6.42%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.865B $2.252B
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00